#VVOS

#VVOS Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

77% Success Rate: Vivos' Non-Surgical Device Transforms Sleep Apnea Treatment for Millions of Children Clinical trial shows Vivos DNA appliance reduces OSA severity by 50%+ in 77% of children, with 93% success in severe cases. Alternative to surgery increases airway volume 67.8%.

#VVOS Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ:VVOS), a medical device company focused on sleep-related breathing disorders, reported Q2 2025 financial results marked by a strategic pivot in their business model. The company completed the acquisition of The Sleep Center of Nevada (SCN), generating approximately $500,000 in diagnostic sleep testing revenue in just 20 days.Q2 2025 financial highlights include revenue of $3.8 million (down from $4.1M in Q2 2024), gross profit of $2.1 million with a 55% margin, and increased operating expenses of $7.0 million. The company ended the quarter with $4.4 million in cash. Additionally, Vivos entered into its first management agreement with MISleep Solutions LLC in Michigan, demonstrating progress in their updated sleep practice management model.

#VVOS Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on treating obstructive sleep apnea (OSA), has announced two strategic executive appointments to support its expansion plans. Michael E. Bruhn joins as Executive Vice President of Business Operations Integration, while Dr. Terry Jones becomes Senior Vice President of Human Resources.Bruhn, formerly EVP and COO at the United States Institute of Peace, will focus on expanding Vivos' operations in the Eastern United States and managing acquisitions integration, including the recent Sleep Center of Nevada acquisition. Dr. Jones, with over 20 years of leadership experience across federal agencies and private sector, will lead human resources strategy to support the company's growth phase.Both executives will report directly to CEO R. Kirk Huntsman as Vivos implements its new business model focused on sleep testing centers and direct patient treatment operations.

#VVOS Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jul 1st - #WETO #ATAI #YYAS #VVOS #VLRS #RUN #RXRX #PL #MNDJF #MDAI #LEU #EOSE #CYN #APLD #BTCS #AEVA #BMNR #ACHC #BGLC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading Tue Jul 1st - #BGLC #VVOS #MESO #IGMS #CLRO #ATAI #WOLF #HUYA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

A cozy bed floats among clouds under a starry night sky with a crescent moon, symbolizing restful sleep. Vivos Therapeutics.

#VVOS just scored Medicare approval for its VidaSleep™ oral appliance, unlocking access for millions battling sleep apnea. With two Medicare-covered solutions now on the market, Vivos is reshaping how OSA is treated—no CPAP required.
#VivosTherapeutics
prismmarketview.com/selling-swee...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance Vivos Therapeutics (NASDAQ: VVOS) has achieved a significant milestone as its VidaSleep™ oral appliance received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.The VidaSleep™ device, featuring Vivos' patented and FDA-cleared Unilateral Bite Block technology, joins the company's mmRNA® device on the PDAC list of covered oral appliances. This dual-PDAC approval makes Vivos the only company with two Medicare-covered oral appliances, expanding access to millions of Medicare beneficiaries.With an estimated 80 million Americans affected by OSA and over 80% of cases undiagnosed, Vivos is targeting the $36 billion sleep therapy market. The VidaSleep™ device is designed to offer a cost-effective solution without compromising efficacy, maintaining strong gross margins while expanding accessibility through Medicare and commercial insurance networks.

#VVOS Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.

#VVOS New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

www.stocktitan.net/news/VVOS/new-clinical-t...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend in Average Directional Index, Mon Jun 23rd - #INLF #GNLX #DWTX #VVOS #RFIL #PXLM #OLPX #NN #IMDX #CCNE #BASE #TXO #TEN #SQNS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

#VVOS completes acquisition of Nevada’s largest sleep center, expanding access to its FDA-cleared OSA treatments. The deal supports a new model focused on higher-margin diagnostic and therapeutic revenues.
#VivosTherapeutics
prismmarketview.com/vivos-comple...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada Vivos Therapeutics (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), marking a significant pivot in its business model. The $6M cash and $1.5M stock deal includes potential additional $1.5M in stock based on performance milestones. SCN, Nevada's largest sleep testing center, sees 3,000 new patients monthly and generates high seven-figure annual revenues. The acquisition was financed through an $8.225M secured loan from Streeterville Capital and a $3.755M private placement from New Seneca Partners. This strategic move shifts Vivos from a dental provider network model to directly managing sleep practices, allowing immediate capture of OSA diagnostic revenue and treatment opportunities. SCN's network of seven locations and 50 beds for sleep testing, led by Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, will now offer Vivos' FDA-cleared OSA treatments to patients, with full integration expected over 12-18 months.

#VVOS Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2025 financial results, showing mixed performance as the company transitions to a new business model. Total revenue decreased to $3.0 million from $3.4 million in Q1 2024, though product revenue increased 8% year-over-year. The company reported a net loss of $3.9 million, slightly higher than the $3.8 million loss in Q1 2024. Operating expenses decreased 5% to $5.4 million, reflecting cost-cutting measures. Notably, Vivos announced plans to acquire The Sleep Center of Nevada for up to $9 million, marking a strategic shift towards direct patient access. The company sold 3,736 oral appliance arches in Q1 2025, generating approximately $1.8 million in revenue. Implementation of new CPT® medical codes for CARE oral medical devices aims to improve reimbursement processes.

#VVOS Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.

#VVOS Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.

#VVOS Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results Sleep disorder treatment innovator Vivos announces FY2024 earnings release and investor call on March 31. Get detailed financial insights and business updates.

#VVOS Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

This Sleep Apnea Treatment is Outperforming CPAP 2-to-1 - Can Vivos Transform Sleep Medicine? Vivos expands FDA-cleared OSA treatment with 64% patient acceptance and 70% margins. New facilities and nationwide sleep center partnerships signal aggressive growth strategy.

#VVOS Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants Vivos Therapeutics raises capital through a direct offering of shares at $4.935 and warrants, with potential for additional $3.4M in proceeds. Details on the strategic financing.

#VVOS Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#VVOS Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#VVOS Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

www.stocktitan.net/news/VVOS/vivos-therapeu...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #VVOS ) Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

#StockMarket #News

1 0 0 0

Posts tagged #VVOS